Akebia Therapeutics vs Ardelyx
AKBA and ARDX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AKBA and ARDX compare
Ardelyx is the larger company, worth 5.9 times as much as Akebia Therapeutics ($770M against $131M).
Ardelyx grew revenue faster over the last twelve months (16.8% versus −12.4% for Akebia Therapeutics).
Ardelyx keeps more of each dollar of sales as profit, with a net margin of −12.4% compared with −22.6% at Akebia Therapeutics.
Ardelyx scores higher on the StockData Score (9 against 4 for Akebia Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AKBA | ARDX |
|---|---|---|
| Size and price | ||
| Market cap | $131M | $770M |
| Share price | $0.474 | $3.09 |
| Change, 1 year | −74.4% | −48.8% |
| Change, 5 years | −82.9% | 209% |
| Beta (5Y) | 1.10 | 0.95 |
| Employees | 194 | 489 |
| StockData Score | ||
| Total score | 4 | 9 (better) |
| Valuation score | 0 | 2 (better) |
| Growth score | 0 | 3 (better) |
| Performance score | 2 | 3 (better) |
| Health score | 2 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 0.7× (better) | 1.7× |
| P/B | 6.5× | 5.2× (better) |
| P/FCF | 9.5× | – |
| FCF yield | 10.5% (better) | −2.3% |
| Fair value | – | $7.50 |
| Margin of safety | – | 58.8% |
| Growth | ||
| Revenue growth (TTM) | −12.4% | 16.8% (better) |
| Revenue growth, 5Y average | −4.3% | 122% (better) |
| Profitability | ||
| Gross margin | 78.9% | 94.4% (better) |
| Operating margin | −15.7% | −7.9% (better) |
| Net margin | −22.6% | −12.4% (better) |
| FCF margin | 7.0% (better) | −4.0% |
| Return on equity | −144% | −38.6% (better) |
| Financial health | ||
| Debt / equity | 2.47 | – |
| Interest coverage | – | −1.6× |
| Current ratio | 1.36 | 3.34 (better) |
| Altman Z-score | −6.30 | −0.13 (better) |
| Piotroski F-score | 7 (better) | 3 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 39.7% | 71.2% |
| Held by insiders | 2.9% | 6.9% |
| Insider net buying, 12 months | −$876K (better) | −$1.9M |
| Short interest, % of float | 10.1% | 12.6% |
Go deeper
- AKBA stock overview
- AKBA income statement
- AKBA valuation and score
- ARDX stock overview
- ARDX income statement
- ARDX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.